Explore current press releases about AOP Health, its products, studies and cooperations. We will be happy to answer any questions or comments you may have via firstname.lastname@example.org
AOP Health presents final results from its CONTINUATION-PV study -up to 7.5 years treatment with BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera patients - at EHA 2022 Annual Meeting
13. 6. 2022
AOP Health Submits New Drug Application for Landiolol, Seeking Approval in the United States
2. 6. 2022
AOP Health opens its Italian base in Pisa
20. 5. 2022
Luana Bortone new Market Access Manager at AOP Health in Italy
23. 2. 2022
Rare Disease Day: Rare Diseases Pose Challenge for Research Community and Require More Integrated Therapies
23. 2. 2022
German Federal Court of Justice upholds AOP's license rights in Ropeginterferon and PEC's liability for damages.
15. 2. 2022
AOP Health donates medication and makes a financial contribution to support the relief efforts in Ukraine
MPN Breakfast 2021
At AOP Health, we have been contributing to research on myeloproliferative neoplasms (MPNs) for many years. On September 9th – the 9th Annual MPN Awareness Day – we especially want to help raising awareness of MPNs, since we believe that informing, connecting and advocating for those who are affected and involved is crucial for the well-being of patients.
Rare disease pioneer AOP Health takes over two health care companies strengthening its position in Europe as well as Austria as a research- and business hub.
"From the beginning, it was our priority to preserve all existing jobs and we have done just that. By developing innovative therapies and a broader territorial presence, we are convinced that we will continue to generate significant growth!"
“I wanted to experience the joy of living and have positive thoughts again. I found various means of helping myself and would like to share this experience with other people.”
Narcolepsy Awareness Day, Sep 22, 2020
Narcolepsy is a rare lifelong neurological disorder that affects the natural cycles of sleeping and waking. It is characterized by excessive sleepiness during the day. This rare disease affects 2–5 out of every 10,000 people. No cure of the disease is currently possible. Therefore the treatment concentrates on relieving the symptoms as far as possible.
Huntington’s Disease Awareness May, 2020
"If you get diagnosed do not hide your head in the sand. Stay open, positive and keep up the hope for a cure. It is important to go on with regular life as long as possible, for example to continue working, meeting friends and family, having hobbies! Such non-medical treatments as regular exercising, physiotherapy, logotherapy and massage etc also have a positive impact!"
PH Awareness Day May 5, 2020
"The time taken to establish the correct diagnosis of chronic thromboembolic pulmonary hypertension is on average about 14 months. However, the disease process starts much earlier - at a time when nobody has any idea about pulmonary hypertension. I know of one case that took 30 years to turn into a manifested disease!"
MPN Awareness Day on Sep 12, 2019
"MPNs is a chronic haematological disease group caused by a stem-cell disorder."
Photos and Infographs
Infograph: Integrated care for rare diseasesBridging the gap to improve the lives of 30 million people in Europe.Infograph: Juggling care and daily lifeThe balancing act of the rare disease community.Rare diseases seriously impact everyday life.
AOP Health Logo
AOP Health Logo
We believe that open communication is essential – not just in our day-to-day contact with business associates, but also with prospective partners, media, interested parties who are not yet familiar with AOP Health. We will be pleased to answer any questions you may have about the company, its products, studies, pipeline and overall plans.
Head of Corporate Communications
+43 676 3131509